Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
A2 Biotherapeutics Inc.
Azienda Ospedaliero-Universitaria di Parma
Verismo Therapeutics
CRISPR Therapeutics
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Context Therapeutics Inc.
Numab Therapeutics AG
NuCana plc
Telix Pharmaceuticals (Innovations) Pty Limited
Medicenna Therapeutics, Inc.
Ascentage Pharma Group Inc.
Cancer Research UK
Novartis
University of Pennsylvania
Mayo Clinic
Checkpoint Therapeutics, Inc.
Aminex Therapeutics, Inc.
UTC Therapeutics Inc.
Prelude Therapeutics
Centre Hospitalier Universitaire Vaudois
Multitude Therapeutics Inc.
Quadriga Biosciences, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Abramson Cancer Center at Penn Medicine
Kantonsspital Winterthur KSW
Chinese PLA General Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)